KalVista Pharmaceuticals is developing novel plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, the leading cause of adult visual loss in developed countries.
Latest News
KalVista Pharmaceuticals Wins £2.4m Biomedical Catalyst Grant to Further Develop Oral Plasma Kallikrein Inhibitors as a Treatment for Diabetic Macular Edema
KalVista Pharmaceuticals and JDRF form research partnership focused on novel approach for treating diabetic eye disease
|
KalVista Pharmaceuticals is an ophthalmology company with a focus on diabetic macular edema
Kalvista Pharmaceuticals Ltd
Building 227
Tetricus Science Park
Porton Down
SP4 0JQ
United Kingdom
t: +44 1980 611755
e: info@kalvista.com
All content © copyright KalVista Pharmaceuticals. All rights reserved 2011.